Evidence map›Paper›PMID 34052363›Full record

ArticleBrain, behavior, and immunity2021

Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation.

Marta Vicente-Rodríguez, Nisha Singh, Federico Turkheimer, Alba Peris-Yague, Karen Randall, Mattia Veronese, Camilla Simmons, Abdul Karim Haji-Dheere, Jayanta Bordoloi, Kerstin Sander and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Brain, behavior, and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Trial
  3. Network-Based Analysis for the Quantification of Brain and Body Immune Axes with Total-Body PET Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. [European journal of nuclear medicine and molecular imaging · 2023
    Article
  12. Imidazoline-I2 PET Tracers in Neuroimaging.International journal of molecular sciences · 2023
    Review
  13. Brain and Systemic Inflammation in De Novo Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Marta Vicente-RodríguezDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom. Electronic address: marta.vicente_rodriguez@kcl.ac.uk.
Nisha SinghDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, United Kingdom.
Federico TurkheimerDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom.
Alba Peris-YagueDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
Karen RandallDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom.
Mattia VeroneseDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
Camilla SimmonsDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom.
Abdul Karim Haji-DheerePET Centre, St Thomas' Hospital, London, United Kingdom.
Jayanta BordoloiSchool of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, United Kingdom.
Kerstin SanderCentre for Radiopharmaceutical Chemistry, University College London, London WC1E 6BS, United Kingdom.
Ramla O AwaisCentre for Radiopharmaceutical Chemistry, University College London, London WC1E 6BS, United Kingdom.
Erik ÅrstadCentre for Radiopharmaceutical Chemistry, University College London, London WC1E 6BS, United Kingdom.
Nima ConsortiumThe Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom.
Diana CashDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom.
Christine A ParkerDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; GlaxoSmithKline, Stevenage, London, United Kingdom; The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom.
Wellcome Centre for Human Neuroimaging · GBKing's College London · GBUniversity College London · GBSt Thomas' Hospital · GB

Funding

Wellcome Trust 104025/Z/14/Z
6 · The paper itself

Abstract

The increased expression of 18 kDa Translocator protein (TSPO) is one of the few available biomarkers of neuroinflammation that can be assessed in humans in vivo by positron emission tomography (PET). TSPO PET imaging of the central nervous system (CNS) has been widely undertaken, but to date no clear consensus has been reached about its utility in brain disorders. One reason for this could be because the interpretation of TSPO PET signal remains challenging, given the cellular heterogeneity and ubiquity of TSPO in the brain. The aim of the current study was to ascertain if TSPO PET imaging can be used to detect neuroinflammation induced by a peripheral treatment with a low dose of the endotoxin, lipopolysaccharide (LPS), in a rat model (ip LPS), and investigate the origin of TSPO signal changes in terms of their cellular sources and regional distribution. An initial pilot study utilising both [

Indexed as

Endothelial CellsPositron-Emission TomographyAnimalsBrainCarrier ProteinsMicrogliaPilot ProjectsRatsReceptors, GABAReceptors, GABA-ACarrier ProteinsReceptors, GABAReceptors, GABA-ATspo protein, ratAstrocytesBiomarkersDPA-714MacrophagesMicrogliaNeuroinflammationNeuronsTSPO

Identifiers

PMID34052363
PMCPMC8323128
OpenAlexW3164352382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.